This article presents the haematopoietic stem cell transplantation (SCT) results of the complete Dutch Fanconi anemia (FA) patient cohort. Sixty-eight Dutch FA patients have been transplanted since 1972. In total, 63 (93%) patients engrafted, 54 after first SCT and 9 after second SCT. Fludarabine (FLU)-based conditioning was associated with decreased graft failure (odds ratio 0.21, p=0.01), decreased early mortality (hazard ratio 0.25, p=0.01) and improved 5-year overall survival (FLU 87.8% [standard error (SE) 5.1%] versus non-FLU 59.3% [SE 9.5%], p=0.01). Late mortality was mainly caused by squamous cell carcinoma. Twenty-two patients were treated with the current Dutch FA conditioning regimen (FLU 150 mg/m 2 and cyclophosphamide 30 mg/kg ± anti-thymocyte globulin -no irradiation). Stem cell source was matched related (n=8) or alternative donors (n=14). Stable engraftment after first SCT was achieved in 19 (86%) patients. At a median follow-up of 3.9 years 20 (91%) patients are alive. Our study provides a unique overview of a nation-wide SCT cohort illustrating the major improvements in treatment regimen and patient outcome in recent years. It shows that a non-irradiation and busulfan-free conditioning regimen can be used successfully, also in alternative donor SCT. Furthermore, it underlines the importance of late cancer screening and comprehensive care for this complex disorder.
Introduction
Fanconi anemia (FA) is a rare chromosomal instability disorder characterized by congenital abnormalities, bone marrow failure (BMF), endocrine disorders and a high-risk of developing malignancies, mainly acute myeloid leukaemia (AML) and squamous cell carcinoma (SCC) (Auerbach, 2009 ). So far the only curative treatment for the hematological manifestations of FA is allogeneic haematopoietic stem cell transplantation (SCT). For FA patients who currently require SCT, the prospects have improved significantly. Over the years, advances in supportive care, donor availability and human leucocyte antigen (HLA) matching have contributed to the improved results of SCT (Remberger et al, 2011) . However, the two major milestones improving outcome of SCT for FA have been the introduction of reduced intensity conditioning regimens and fludarabine (FLU) (MacMillan & Wagner, 2010) .
SCT for FA was reported for the first time in the mid-1970's (Dooren et al, 1974 , Barrett et al, 1977 . Initially, outcome was poor, mainly due to toxicity of the applied conditioning regimens (Deeg et al, 1983 , Gluckman et al, 1984 . Hypersensitivity to DNA damaging agents was suspected and proven in vitro and reduced intensity conditioning regimens were introduced, resulting in less toxicity and increased survival in matched sibling donor SCT (Berger et al, 1980 , Auerbach et al, 1983 , Gluckman et al, 1983 , Gluckman et al, 1990 , Kohli-Kumar et al, 1994, Socie et al, 1998 , Dufour et al, 2001 ). However, results of alternative donor transplant remained poor, mainly because of graft failure and graftversus-host-disease (GVHD) (Hows et al, 1989 , Gluckman et al, 1995 , Zwaan et al, 1998 , Guardiola et al, 2000 , MacMillan et al, 2000 . In 1997, FLU, a purine analog that inhibits DNA synthesis, was introduced (Kapelushnik et al, 1997 , Aker et al, 1999 . The effectiveness and relative safety of FLU in HLA-matched sibling SCT was confirmed by several groups (Tan et al, 2006 , Stepensky et al, 2011 , Ayas et al, 2012 . Even more important, FLU also improved outcome in alternative donor SCT (Boulad et al, 2000 , de Medeiros et al, 2006 , Yabe et al, 2006 , Wagner et al, 2007 .
The current results of alternative donor SCT for FA are very encouraging. Recently, a 5-year overall survival of 94% was reported in 17 patients without prior opportunistic infections or transfusions who were transplanted after a 3Gy total body irradiation (TBI) + cyclophosphamide (CY) + FLU + anti-thymocyte globulin (ATG) conditioning regimen (MacMillan et al, 2015) . Also a chemotherapy only conditioning regimen for alternative donor SCT, performed in 17 patients and consisting of CY + FLU + busulfan (BU) + alemtuzumab, resulted in excellent short-term outcome (Chao et al, 2015) . Next steps in SCT for FA are further optimization of conditioning regimens and thereby reduction of possible long-term side effects. Elimination of irradiation and BU, proven to be a successful approach in matched sibling donor SCT, would also be attractive for FA patients transplanted with stem cells from alternative donors.
The first SCT for FA in the Netherlands was performed in 1972. We present the characteristics and results of all consecutive SCTs that were performed in FA patients in the Netherlands over the past 4 decades, illustrating the major advances that have been made over time. Furthermore, we report the results of the current Dutch non-irradiation and BU-free conditioning regimen for FA patients with matched sibling as well as alternative donor SCT.
Methods

Patients
We retrospectively analysed the characteristics and outcome of all consecutive FA patients who received a SCT in the Netherlands since 1972. Data were collected from medical charts and processed anonymously in a dedicated study database. SCTs were included until August 2014 and follow-up was performed from time of SCT until June 2015. The study was approved by the Institutional Review Board of the University Medical Center Utrecht (Medical Ethical Committee number 12/467) and the need for informed consent was waived. Nevertheless, according to national policy, all patients that undergo SCT give informed consent for treatment and future use of medical data for research purposes.
Transplant characteristics
Indication for SCT was defined as BMF, myelodysplastic syndrome (MDS) and/or clonal abnormalities, or leukaemia. BMF was defined as persistent transfusion need and/or severe neutropenia (neutrophil count < 0.5x10 9 /L). MDS was defined as the presence of high-risk cytogenetic abnormalities (e.g. monosomy 7) and/or morphological signs of dysplasia, as reviewed by the Dutch National Pediatric Bone Marrow Review Board. All stem cell sources (bone marrow, cord blood, peripheral blood stem cells [PBSCs]) were included. Stem cell donors were defined as matched related donors (MRD, HLA match 10/10 or 6/6 in case of cord blood), mismatched related donors (mMRD, HLA match ≤ 9/10), matched unrelated donors (MUD, HLA match ≥ 9/10 or 6/6 in case of cord blood) and mismatched unrelated donors (mMUD, HLA match < 9/10 or ≤ 5/6 in case of cord blood). HLA typing was performed by licensed laboratories according to state-of-the-art technologies.
Outcomes
Primary outcome was overall patient survival. Overall survival time was defined as the
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time between transplantation and date of death from any cause or date of last follow-up for survivors. Mortality was classified as early mortality, defined as death within 1 year after SCT, and late mortality, defined as death more than 1 year after SCT. Secondary outcomes were graft failure, haematopoietic recovery, acute GVHD (aGVHD) and chronic GVHD (cGVHD). Graft failure was defined as either no engraftment (primary graft failure) or loss of the graft after initial engraftment (secondary graft failure). Chimerism, analysed routinely since 2000, was analysed in licensed laboratories using state-of-the-art technologies. Full donor chimerism was defined as ≥ 95% donor signal. Neutrophil and platelet recovery was defined as the first of 3 consecutive days with an absolute neutrophil count greater than 0.5x10 9 /L and an unsupported platelet count greater than 50x10 9 /L, respectively. Patients with aGVHD ≥ grade II, graded according to the Glucksberg criteria Przepiorka et al, 1995) , were included in the statistical analysis to study factors potentially associated with aGVHD. At the time of the study the following cGVHD classification was used for engrafted patients with a follow-up of more than 100 days after last SCT: limited cGVHD in case of localized skin involvement with or without hepatic dysfunction and extensive cGVHD in case of all other manifestations of cGVHD.
Statistical analysis
Continuous variables are displayed as median, interquartile range (IQR) and range. Discrete variables are displayed as counts and proportions. The Fisher's exact test (2-sided) was used to compare proportions between groups. Univariate logistic regression was used to study factors potentially associated with engraftment and GVHD in patients with stable engraftment after first or second SCT. The Kaplan-Meier method was used to analyse overall survival. Survival comparison between groups was made using the TaroneWare test. Univariate Cox regression analysis was employed to study factors potentially associated with early and late mortality, including age (as continuous variable), gender, SCT indication, stem cell donor, stem cell source, conditioning regimen, ex vivo T-cell depletion (TCD), number of SCT and GVHD. 
Results
Patient and transplant characteristics
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Engraftment and haematopoietic recovery
Fifty-four of the 68 (79.4%) patients had a stable engraftment after first SCT. Two patients died shortly after transplant before engraftment occurred. Graft failure was seen in 12 patients (primary graft failure n=7, secondary graft failure n=5, see detailed description in Table SII ), all of whom were transplanted for BMF. Eleven of them received a second transplant, 9 of whom engrafted. Median time to neutrophil and platelet recovery in the 63 engrafted patients was 20 days (IQR 16-27 days) and 34 days (IQR 23-61 days), respectively. Chimerism was analysed in 54 of the 63 engrafted patients and showed full donor signal in 89% (48 of 54 patients). 
Acute and chronic GVHD
Twelve of the 63 (19%) patients with engraftment after first or second SCT developed acute GVHD grade ≥ II of whom 7 had aGVHD grade III-IV. Information on ex vivo TCD was available for 59 of the 63 engrafted patients. Ex vivo TCD was performed in 12 of 59 patients of whom none developed aGVHD, whereas no ex vivo TCD was performed in 47 of 59 patients of whom 9 developed aGVHD (Fisher's exact p=0.18). No potential risk factors associated with aGVHD were found (see Table III ). Six of the 55 (11%) engrafted patients with a follow-up of more than 100 days after last SCT developed cGVHD. Two patients had limited and four patients had extensive cGVHD. Information on ex vivo TCD was available for 54 of the 55 evaluable patients; cells from 10 of these 54 patients underwent ex vivo TCD and none of these patients developed cGVHD, whereas no ex vivo TCD was performed in 44 of 54 patients of whom 6 developed cGVHD (Fisher's exact p=0.58). Logistic regression analysis was performed and no potential risk factors associated with cGVHD were found (see Table III ).
Survival
Cumulative survival estimates are shown in Fig 1. Five-year overall survival was 76.4% (standard error [SE] 5.2%) at a median follow-up of 5.5 years (range 0-23.6 years, Fig 1A) . In the FLU group 5-year overall survival was significantly better than in the non-FLU group (FLU 87.8% (SE 5.1%) versus non-FLU 59.3% (SE 9.5%), p=0.01, Fig 1B) . Survival in all donor groups has improved markedly since the introduction of FLU, with a 5-year overall survival of 91% (SE 8.7%) in the FLU-MRD group. Five-year overall survival after alternative donor SCT has significantly increased from 50% (SE 15.8%) to 86.7% (SE 6.2%), p=0.01. The 1-year overall survival in adult patients was 50% (SE 20.4%). Two of the 14 high-risk patients relapsed (one ALL, one MDS, refractory anemia with excess blasts type 2). Five-year overall survival was 78.6% (SE 11%) at a median follow-up of 4.1 years (range 0.1-16.7 years). Three patients died, one from relapse ALL, one from aGVHD and one from infection (see detailed description on pre-transplant chemotherapy and outcome in high-risk patients in Table SI ).
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Current Dutch conditioning regimen
The current Dutch conditioning regimen for FA patients, introduced in 2007, consists of FLU 150 mg/m 2 + CY 30 mg/kg ± ATG and no irradiation, and has been used in 22 patients so far. Stem cell donors were MRD (n=8), mMRD (n=2), MUD (n=10) and mMUD (n=2). Patient characteristics and detailed description are presented in Table IV . Stable engraftment was achieved in 19 of 22 (86%) patients. Graft failure was seen in 1 mMUD SCT and in 2 ex vivo TCD mMRD SCTs. Two patients with graft failure successfully engrafted after second SCT and one patient needed 4 SCTs (see Table SII ). Of the 19 patients with stable engraftment after first SCT 14 showed full donor chimerism and 5 mixed chimerism. Three of the 5 patients with mixed chimerism did not receive ATG in the conditioning regimen.
Acute GVHD grade ≥ II was seen in 2 of 19 (11%) engrafted patients and none of the patients developed cGVHD. Median follow-up was 3.9 years (range 0.8-7.9). Two of the 22 patients treated with the current Dutch conditioning regimen died; one of severe aGVHD (75 days after SCT) and one of bronchiolitis obliterans and fungal infection (56 days after last SCT). Five-year overall survival in the 8 MRD patients and 14 alternative donor patients was 100% and 85.7% (SE 9.4%), respectively (see Fig 1C) .
Discussion
For Dutch FA patients who currently require SCT, the prospects have improved markedly. With the current Dutch non-irradiation and BU-free conditioning regimen SCT can be performed safely and effectively in most patients. Nevertheless, challenges remain in specific FA subgroups. Furthermore, the improved results of SCT reveal new long-term challenges for patients with FA.
Non-irradiation BU-free conditioning regimen for alternative donor SCT
Successful elimination of irradiation in alternative donor SCT was reported recently by Chao et al (2015) . After a CY + FLU + BU + alemtuzumab regimen, engraftment was seen in all patients (n=17) and 2-year overall survival was 88% (Chao et al, 2015) . Further elimination of BU would be attractive but challenging, given the history of graft failure in alternative donor SCT for FA. Since 2008 we transplanted 14 patients with stem cells of alternative donors after a FLU -CY ± ATG preparative regimen. Our results indicate that a non-irradiation and BU-free conditioning regimen can be used successfully also in alternative donor SCT. Nevertheless, this regimen appears to be insufficient for stable engraftment in haplo-identical donor SCT.
Challenges in specific subgroups
In the Dutch cohort FLU significantly improved engraftment, especially in MUD SCT. However, engraftment after transplant with stem cells from mMRDs, almost exclusively haplo-identical donors, was significantly lower despite the use of FLU. Of the FLU-haplo SCTs, all ex vivo TCD, only the patients treated with additional irradiation and the patient that received thiothepa engrafted, suggesting that the standard FLU-based conditioning regimen without irradiation is not sufficient for stable engraftment of haplo-identical transplants. A recent publication reported the results of the largest series of T-cell depleted haplo-identical SCT in FA (Zecca et al, 2014) . Nine of the 12 patients (75%) engrafted after a FLU-based conditioning 
New challenges
The excellent outcome in young FA patients and the moderate survival in adult patients and patients with advanced MDS or leukaemia leads to the question whether or not all FA patients, if diagnosed at young age, should be transplanted early after diagnosis. Should SCT be performed for all FA patients or only when strict criteria are reached, such as progressive BMF? What to do in case of mild BMF in young adolescent FA patients, knowing that their prospects will decline with increasing age or the development of MDS/leukaemia, while
4
on the other hand the SCT related morbidity and mortality are considerable? Decision analytical models are being developed to support decision making (Khan et al, 2015) . Because of the increased life expectancy FA is no longer only a disease of childhood and FA patients are increasingly being referred to physicians involved in adult healthcare. In general, these physicians, understandably, have little experience with this rare, complex disorder. A survey to evaluate current healthcare for FA in the Netherlands, conducted in collaboration with the Dutch FA patient organization, shows that transition from pediatric to adult healthcare is difficult and needs to be optimised (Smetsers et al, 2014) . Comprehensive care for children and adults, with special attention for transition, is necessary to bridge the current gap between pediatric and adult healthcare. New questions, raised as a consequence of the increased lifespan, such as fertility preservation in now surviving adult patients, need to be addressed. In our cohort SCC was the cause of death in 4 patients. Long-term follow-up studies have shown that transplanted FA patients develop SCC earlier and more frequently compared to non-transplanted FA patients (Rosenberg et al, 2005 
Conclusions and recommendations
This report presents a unique overview of a complete national cohort of FA patients undergoing SCT over time. Dutch SCT results have improved markedly. This improvement is associated with the introduction of FLU, nevertheless, potential confounding factors such as refinement of supportive care, donor availability and HLA matching over the years are difficult to assess and should be taken into account. Our study shows that a non-irradiation and BU-free conditioning regimen can be used successfully also in alternative donor SCT, but not in haplo-identical SCT. Challenges remain in specific subgroups of FA patients. Patients diagnosed with FA at an older age or at time of advanced MDS or leukaemia will need tailored therapy to improve their chances of survival. More intensive conditioning regimens are needed in patients with haplo-identical donor SCT to ensure engraftment. The observed late mortality due to SCCs in the second and third decade after SCT underlines the critical importance of lifelong and frequent surveillance for cancer as well as on-going comprehensive care, research and expert counselling in this rare and complex disorder. 
